Richard Shames - Protagonist Therapeutics Chief Medical Officer
| PTGX Stock | USD 52.65 0.40 0.75% |
Executive
Dr. Richard S. Shames, M.D., serves as Chief Medical Officer of the Company. He currently also serves as Adjunct Associate Clinical Professor of Pediatrics at Stanford University. Prior to joining Protagonist, he served as Senior Vice President and Chief Medical Officer at Aldea Pharmaceuticals, from 2013 to 2015. Prior to Aldea, Dr. Shames was Distinguished Scientist, Clinical Research and Early Biologics Lead at Merck Co., Inc., from 2009 to 2013. Prior to joining Merck, Dr. Shames held positions of increasing responsibility at Facet Biotech, from 1999 to 2009, most recently as Therapeutic Head of Immunology and Senior Medical Director. Prior to Facet, Dr. Shames held full time clinical faculty positions in Pediatric Allergy and Clinical Immunology at Stanford University, from 1996 to 1999, and the University of California, San Francisco Schools of Medicine, from 1993 to 1996 since 2015.
| Age | 64 |
| Tenure | 10 years |
| Address | 7707 Gateway Boulevard, Newark, CA, United States, 94560 |
| Phone | 510 474 0170 |
| Web | https://www.protagonist-inc.com |
Protagonist Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.2866 % which means that it generated a profit of $0.2866 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5439 %, meaning that it created $0.5439 on every $100 dollars invested by stockholders. Protagonist Therapeutics' management efficiency ratios could be used to measure how well Protagonist Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.39 in 2025. Return On Capital Employed is likely to rise to 0.38 in 2025. At this time, Protagonist Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 160.7 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 141.3 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Matthew Moore | Ventyx Biosciences | 52 | |
| Mick OQuigley | Ideaya Biosciences | N/A | |
| Catriona Yale | Akero Therapeutics | 53 | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Ronald MD | Arvinas | 58 | |
| Adam JD | Day One Biopharmaceuticals | 58 | |
| Sharon Klahre | Syndax Pharmaceuticals | N/A | |
| Delphine Imbert | Pliant Therapeutics | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Andres CPA | Ideaya Biosciences | 38 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Kathleen MD | Verona Pharma PLC | 67 | |
| MS MBA | Kura Oncology | 51 | |
| Pamela Esposito | Replimune Group | 50 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Moriarty ESQ | Avidity Biosciences | 56 | |
| Colin Love | Replimune Group | 66 | |
| Peter Rahmer | Relay Therapeutics | N/A | |
| Lisa Sinclair | Arvinas | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
Management Performance
| Return On Equity | 0.54 | ||||
| Return On Asset | 0.29 |
Protagonist Therapeutics Leadership Team
Elected by the shareholders, the Protagonist Therapeutics' board of directors comprises two types of representatives: Protagonist Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagonist. The board's role is to monitor Protagonist Therapeutics' management team and ensure that shareholders' interests are well served. Protagonist Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagonist Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mohammad Masjedizadeh, Executive Officer | ||
| Abha Bommireddi, Executive Management | ||
| Newman Yeilding, Chief EVP | ||
| Matthew JD, Executive Counsel | ||
| Ashok Bhandari, Vice President - Chemistry | ||
| Matthew Gosling, Executive Counsel | ||
| Richard Shames, Chief Medical Officer | ||
| Dinesh Patel, President CEO, Director | ||
| David Liu, Chief Scientific Officer, Head of Research & Development | ||
| Carena Spivey, Senior Resources | ||
| Suneel Gupta, Executive Vice President of Clinical Operations and Clinical Pharmacology | ||
| Mark Smythe, Vice President -Technology & Alliances | ||
| Scott MD, Executive Gastroenterology | ||
| FACP MD, Chief Officer | ||
| Carter King, Executive Development | ||
| Asif Ali, Executive Officer |
Protagonist Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagonist Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.54 | ||||
| Return On Asset | 0.29 | ||||
| Profit Margin | 0.63 % | ||||
| Operating Margin | 0.74 % | ||||
| Current Valuation | 2.82 B | ||||
| Shares Outstanding | 61.38 M | ||||
| Shares Owned By Insiders | 1.38 % | ||||
| Shares Owned By Institutions | 98.62 % | ||||
| Number Of Shares Shorted | 4.22 M | ||||
| Price To Earning | (4.81) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.